Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic DermatitisLisa A. Beck, Arsalan Shabbir, Ryszard Galus et al.|American Journal of Clinical Dermatology|2022Cited by 104
Dupilumab reduces inflammatory biomarkers in pediatric patients with moderate-to-severe atopic dermatitisLisa A. Beck, Ainara Rodríguez Marco, Antonella Muraro et al.|Journal of Allergy and Clinical Immunology|2024Cited by 25